STOCK TITAN

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that Barry Quart, CEO, and John Poyhonen, President, will engage in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. The event is scheduled for September 27, 2021, at 1:20 pm ET. A live webcast will be accessible via the company's website, with a replay available for 60 days post-event. Heron Therapeutics focuses on developing advanced treatments to meet significant unmet patient needs in acute care and oncology. For further details, visit www.herontx.com.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer, and John Poyhonen, President and Chief Commercial Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 1:20 pm ET.

A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section. A replay of the event will be archived on the site for 60 days.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-Looking Statements 

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact: David Szekeres, Executive Vice President, Chief Operating Officer, Heron Therapeutics, Inc., dszekeres@herontx.com, 858-251-4447

Cision View original content:https://www.prnewswire.com/news-releases/heron-therapeutics-to-present-at-the-2021-cantor-virtual-global-healthcare-conference-301381949.html

SOURCE Heron Therapeutics, Inc.

FAQ

When is the Heron Therapeutics fireside chat at the Cantor Virtual Global Healthcare Conference?

The fireside chat will take place on September 27, 2021, at 1:20 pm ET.

Where can I watch the Heron Therapeutics conference webcast?

The live webcast will be available on Heron Therapeutics' website under the Investor Resources section.

Will there be a replay of the Heron Therapeutics conference event?

Yes, a replay of the event will be archived on the website for 60 days.

Who will represent Heron Therapeutics at the Cantor Virtual Global Healthcare Conference?

Barry Quart, the CEO, and John Poyhonen, the President, will represent Heron Therapeutics.

What is the focus of Heron Therapeutics?

Heron Therapeutics is focused on developing best-in-class treatments to meet important unmet patient needs in acute care and oncology.

Heron Therapeutics, Inc.

NASDAQ:HRTX

HRTX Rankings

HRTX Latest News

HRTX Stock Data

237.27M
150.99M
0.71%
81.57%
18.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO